Dr Joshua Richter and Dr Peter Forsberg review key trial data and dosing strategies for selinexor based combinations.
EP. 1: An Overview of Treatment Options Available for Patients with R/R MM
Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.
EP. 2: Key Trial Data Supporting the Use of Selinexor in Patients with R/R MM
Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.
EP. 3: Dosing Strategies and Adverse Events in Patients Treated with Selinexor
Discourse centered around dosing strategies for selinexor-based therapies.
EP. 4: Practical Considerations for Reducing Risk and Providing Supportive Care
Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies
EP. 5: Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM Landscape
Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.
EP. 6: Recap: A Review of Selinexor Combination Therapies in Relapsed/Refractory Multiple Myeloma
In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.
2 Clarke Drive Cranbury, NJ 08512